AstraZeneca

AstraZeneca | December 08, 2016

AstraZeneca’s $1.1 billion cost-cutting effort has taken its latest round of jobs. Facing the prospect of lower U.S. revenues next year, the company has pulled the trigger on “necessary, but difficult decisions” to chop 700 positions.AstraZeneca will eliminate the jobs throughout its U.S. commercial organization and North American headquarters in Wilmington, DE, where about 120 positions have been cut, according to a spokesperson. The remaining are field-based sales and nonsales jobs.“While thes...

AstraZeneca | March 28, 2017

AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company's next wave of innovative oncology medicines, at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 2017....

European Pharmaceutical Review | April 04, 2017

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR)....

BioPharma Dive: Biotech and Pharma news | May 03, 2017

Small Boston-based Pieris Pharmaceuticals is joining forces with AstraZeneca to speed development of its protein platform for application in respiratory diseases, announcing Wednesday a broad collaboration with the British pharma....